Gaviscon Double Action Liquid (Mint Flavour)

Name and Strength of Active Substance(s)
Sodium Alginate 500mg/10ml, Sodium Bicarbonate 213mg/10ml and Calcium Carbonate 325mg/10ml.

Product Description
Oral Suspension. An off white suspension with odour and flavour of Cool Mint.

Pharmacodynamics
On ingestion, Gaviscon reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents effectively (up to 4 hours) impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect. Calcium Carbonate neutralises gastric acid to provide fast relief from indigestion and heartburn. This effect is increased by the addition of sodium bicarbonate which also has a neutralising action. The total neutralizing capacity of the product at the lowest dose of 10 ml is approximately 10 mEqH. Evidence shows the rapid onset of Gaviscon in soothing relief within 4 minutes*.

*Reference: Strugala V, et al. A Randomized, controlled, crossover trial to investigate times to onset of theperception of soothing and cooling by-over the counter heartburn treatments. J Int MedRes.2010;38(2):449-457.)

Pharmacokinetics
The mode of action of this medicinal product is physical and does not depend on absorption into the systemic circulation.

Indication
Treatment of acid related symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion, for example following meals or during pregnancy and for symptons of excess stomach acid (hyperacidity).

Recommended Dosage
Adults and children 12 years and over: Take 10-20 ml after meals and before bedtime, up to four times a day.
Children under 12 years old: Should only be taken on medical advice.
Elderly: No dose modifications necessary for this age group.

Route of Administration
Oral

Contraindications

Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens).

Warnings and Precautions

Each 20 ml dose has a sodium content of 254.5 mg (11.06 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each 20 ml contains 260 mg (6.5 mmol) of calcium. Care needs to taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. If symptoms do not improve after seven days, the clinical situation should be reviewed.

Interactions with Other Medicaments

None Known.

Pregnancy and Lactation

Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gaviscon on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience the medicinal product may be used during pregnancy and lactation.

Side Effects

Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic
or anaphylactoid reactions. Ingestion of large quantities of calcium carbonate may cause alkalosis, hypercalcaemia, acid rebound, milk alkali syndrome or constipation. These usually occur following larger than recommended dosages

Symptoms and Treatment of Overdose

In the event of overdosage symptomatic treatment should be given. The patient may notice abdominal distension.

Storage Conditions

Do not store above 30℃. Do not refrigerate or freeze.

Dosage forms and packaging available

Oral Solution. Available in bottles and sachets form. 150ml, 200ml, 300ml, 500ml and 600ml. 10ml x 1 unit, 10ml x 10 units, 10ml x 10 units and 10ml x 24 units

Manufacturer and Product License Holder in UK:

Reckitt Benckiser Healthcare (UK) Limited, Hull, HU8 7DS, UK

Product Registration Holder:

RB(Health) Malaysia Sdn. Bhd.
Level 17, Menara One Sentrum,

No.201, Jalan Tun Sambanthan,
50470 Kuala Lumpur.

Reckitt Benckiser (Singapore) Pte Ltd,
12 Marina Boulevard #19 – 01,
Marina Bay Financial Centre, Tower 3,
Singapore 018982.

Revision Date:
06 January 2025